Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models
Journal of Clinical Investigation · 03.09.2024 · 134 (17)
DOI: 10.1172/jci177606 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 03.09.2024. Verfasst von Svena Verma und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology Program. Hauptthemen laut MEDLINE: Glucose, Tumor Microenvironment, L-Lactate Dehydrogenase. Die Arbeit wurde bisher 106-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Tumor reliance on glycolysis is a hallmark of cancer. Immunotherapy is more effective in controlling glycolysis-low tumors lacking lactate dehydrogenase (LDH) due to reduced tumor lactate efflux and enhanced glucose availability within the tumor microenvironment (TME). LDH inhibitors (LDHi) reduce glucose uptake and tumor growth in preclinical models, but their impact on tumor-infiltrating T cells is not fully elucidated. Tumor cells have higher basal LDH expression and glycolysis levels compared with infiltrating T cells, creating a therapeutic opportunity for tumor-specific targeting of glycolysis. We demonstrate that LDHi treatment (a) decreases tumor cell glucose uptake, expression of the glucose transporter GLUT1, and tumor cell proliferation while (b) increasing glucose uptake, GLUT1 expression, and proliferation of tumor-infiltrating T cells. Accordingly, increasing glucose availability in the microenvironment via LDH inhibition leads to improved tumor-killing T cell function and impaired Treg immunosuppressive activity in vitro. Moreover, combining LDH inhibition with immune checkpoint blockade therapy effectively controls murine melanoma and colon cancer progression by promoting effector T cell infiltration and activation while destabilizing Tregs. Our results establish LDH inhibition as an effective strategy for rebalancing glucose availability for T cells within the TME, which can enhance T cell function and antitumor immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacology Program.
- Swim Across America, and Ludwig Collaborative Laboratory, Department of Pharmacology.
- Sandra and Edward Meyer Cancer Center.
- Department of Medicine.
- Immunology and Microbial Pathogenesis Program.
- Parker Institute for Cancer Immunotherapy, Weill Cornell Medicine, New York, New York, USA.
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Verma, S., Budhu, S., Serganova, I., Dong, L., Mangarin, L. M., Khan, J. F., Bah, M. A., Assouvie, A., Marouf, Y., Schulze, I., Zappasodi, R., Wolchok, J. D., & Merghoub, T. (2024). Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models. Journal of Clinical Investigation, 134(17). https://doi.org/10.1172/jci177606
Vancouver
Verma S, Budhu S, Serganova I, Dong L, Mangarin LM, Khan JF, et al. Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models. Journal of Clinical Investigation. 2024;134(17). doi:10.1172/jci177606
BibTeX
@article{Verma2024,
author = {Verma, Svena and Budhu, Sadna and Serganova, Inna and Dong, Lauren and Mangarin, Levi M and Khan, Jonathan F and Bah, Mamadou A and Assouvie, Anais and Marouf, Yacine and Schulze, Isabell and Zappasodi, Roberta and Wolchok, Jedd D and Merghoub, Taha},
title = {Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models},
journal = {Journal of Clinical Investigation},
year = {2024},
volume = {134},
number = {17},
doi = {10.1172/jci177606}
}
EUVIMED